Effects of tafamidis on pacemaker therapy

17 May 2025 (09:00 - 09:53)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Margarida Figueiredo

Hospital N.S. Rosario, Barreiro (Portugal)

8 More presentations in this session

Presentation thumbnail

Clinical characteristics, mortality outcomes and survival predictors of transthyretin cardiac amyloidosis in an Asian registry

Doctor V. Putri (Singapore, SG)

Abstract Slides Video

Presentation thumbnail

A descriptive journey through the heart of transthyretin cardiac amyloidosis

Doctor M. Rodrigues Simoes (Coimbra, PT)

Abstract Slides Video

Presentation thumbnail

Diagnostic value of the right ventricular wall thickness and free wall strain ratio in distinguishing hypertrophic cardiomyopathy and wild-type transthyretin cardiac amyloidosis

Doctor E. Mata (Creixomil, PT)

Abstract Slides Video

Presentation thumbnail

Red-flags for cardiac amyloidosis in real life of an internal medicine department

Doctor I. Fiteni Mera (Zaragoza, ES)

Abstract Slides Video

Presentation thumbnail

Associations between age and sex and cardiovascular outcomes in patients with non-obstructive hypertrophic cardiomyopathy

Doctor P. Gebrehiwet (South San Francisco, US)

Abstract Slides Video

Access the full session

Session thumbnail

ePosters in myocardial disease (2)

The Event

Event poster

Heart Failure 2025

17 May 2025 09:00 CET

You may be interested in

Congress Presentation

Tafamidis for the treatment of transthyretin cardiac amyloidosis (ATTR-CM) - Real-world data from a tertiary center.

Congress Presentation

Tafamidis for the treatment of transthyretin cardiac amyloidosis (ATTR-CM) - Real-world data from a tertiary center.

Congress Presentation

Tafamidis reduces the burden of atrial fibrillation in patients with wild-type transthyretin amyloid cardiomyopathy

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources